#couldtransform

The Bengaluru startup transforms early disease detection in cancer diagnostic

Bengaluru's Quantum Biosciences Private Limited, a deep-tech business, is pioneering quantum technologies to detect tissue and cellular damage before symptoms manifest. This “predictive tech” could revolutionise early diagnosis in several medical specialities and create a “quantum” leap in cancer care.

Read about Fujitsu's 10000+ superconducting Qubit quantum computers.

Quantum Biosensors for Unprecedented Knowledge

Quantum Biosciences' quantum biosensor can detect oxidative stress's ‘magnetic fingerprints’ in cells, its key breakthrough. Since oxidative stress predicts cellular damage, these magnetic signals can detect tissue damage early. Unlike MRI, PET scans, and blood indicators, Quantum Biosciences can discover abnormalities in hours, possibly changing patient outcomes.

Quantum Biosciences Managing Director Ravi Puvvala said conventional diagnostic methods rarely detect early signs. It said that blood biomarkers, MRIs, and PET scans only detect damage after it has caused significant harm. Early identification is crucial for fast action and boosts medication efficacy and reduces long-term risks.

Quantum biosensors

The Bengaluru-based deep-tech startup Quantum Biosciences Private Limited is developing quantum biosensors, a cutting-edge “predictive tech”.

These are some key quantum biosensor properties.

Detection Mechanism

They detect cell oxidative stress “magnetic fingerprints”. Cellular damage is indicated by oxidative stress. This approach detects magnetic signals to detect tissue damage early. Quantum biosensors use quantum technology. They detect magnetic biomarkers and subcellular free radicals at the quantum level. The goal is to detect tissue and cellular damage before symptoms appear. Healthcare Goal and Use

By improving early detection, this “quantum leap” could change cancer care. It aims to identify in hours, dramatically improving patient outcomes. It could predict radiation-induced cardiotoxicity and other chronic disorders before irreversible harm, inspired by Quantum Biosciences Managing Director Ravi Puvvala's experience. The approach may be used in nephrology, cardiovascular disease, and neurodegenerative disorders after the basic process is understood. Quantum Flag Qubits Correct Quantum Circuit Errors

Individual Motivation Drives Innovation

Ravi Puvvala's breakthrough invention has personal roots. Watching their spouse struggle through cancer treatment inspired it. The woman had radiation therapy, which kills healthy and cancerous cells but is important for cancer treatment. Chronic non-discriminatory damage causes weariness, cognitive decline, organ failure, secondary cancers, and even fibrosis or heart disease. Puvvala saw his husband suffer such repercussions.

After 15 years inventing sensors for the automotive industry, Puvvala wanted to apply his skills to solve this medical problem. Before irreparable cardiac damage, they investigated using sensors to predict radiation-induced cardiotoxicity. This individual pursuit led to quantum sensors for early diagnosis.

Platform Technology and Strategic Partnerships

Puvvala's cooperation with QT Sense, a Netherlands-based company managed by Indian Deepak Veeragowda, was a “quantum leap” for Quantum Biosciences. QT Sense was founded to commercialise 15 years of University of Groningen research.

The alliance uses Quantum Nuova from QT Sense, a sophisticated platform technology for quantum event detection. Magnetic biomarkers and subcellular free radicals are fundamental to Quantum Biosciences' technique. “For two years, it has investigated different potential technologies for early stage diagnostics,” Puvvala said. It examined quantum and classical sensors, and quantum biosensors can be developed to harness quantum sensors' potential.

See also Quantum Sensing Applications Near Industry Marketing

Future Direction: Validation and Collaboration

Quantum biosensors can detect subcellular stress, but interpreting these results is crucial. Puvvala stressed the need for greater research to link cellular stress to biomarkers for accurate prognoses. More research is needed to connect cellular stress to a biomarker for diagnosis.

Subcellular detection validation is important to the company. “It can actually go inside the cell and measure all kinds of things for the first time,” Puvvala said. These measurements must now be interpreted using clinical testing. Therefore, one must create a diagnostic system and test. Quantum Biosciences will collaborate with Indian and international institutions over the next two years to achieve this. It will seek partnerships with cancer centres to gather important data.

“It’s need a whole village to build this technology,” Puvvala remarked, emphasising teamwork. Everyone needs medical and engineering teams and integrators like us. Quantum Biosciences is building its core research skills at the Centre for Cellular and Molecular Platforms (C-CAMP), a Department of Biotechnology, Ministry of Science and Technology, Government of India project.

Furthermore, the Centre for Nano Science and Engineering at the Indian Institute of Science (IISc) in Bengaluru hosts them. They are also building a common infrastructure for clinical applications and deep-science research with state-level innovation initiatives and ecosystem players.

Impact on Indian and Global Healthcare Beyond oncology, Quantum Biosciences' technology has far-reaching effects. Once the “very base-level mechanism” is mastered, Puvvala believes the approach could treat nephrology, cardiovascular illness, and neurodegenerative disorders.

Additionally, this invention could tackle India's basic healthcare challenges. One of the things that was highlighted at the meeting is that most hospitals are overloaded since primary and critical care have been combined,” Puvvala said. The quantum biosensor may alleviate primary healthcare load by quickly recognising critical cases.